Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review

详细信息    查看全文

• 作者：Giacomo Gastaldi^a ; ^{giacomo.gastaldi@hcuge.ch}Author Vitae ; Nicolas Goossens^bAuthor Vitae ; Sophie Clé ; ment^cAuthor Vitae ; Francesco Negro^b ; ^cAuthor Vitae
• 关键词：HCV ; Diabetes ; Insulin resistance ; Inflammation ; Steatosis ; Direct-acting antivirals
• 刊名：Journal of Advanced Research
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：8
• 期：2
• 页码：149-159
• 全文大小：1030 K
• 卷排序：8

文摘

The association between hepatitis C virus (HCV) infection and type 2 diabetes (T2D) has been known for over 20 years. Cross-sectional and longitudinal studies have shown a higher prevalence and incidence, respectively, of T2D in patients with chronic HCV infection. HCV induces glucose metabolism alterations mostly interfering with the insulin signaling chain in hepatocytes, although extrahepatic mechanisms seem to contribute. Both IR and T2D accelerate the histological and clinical progression of chronic hepatitis C as well as the risk of extra-hepatic complications such as nephropathy, acute coronary events and ischemic stroke. Before the availability of direct-acting antivirals (DAAs), the therapeutic choice was limited to interferon (IFN)-based therapy, which reduced the incidence of the extra-hepatic manifestations but was burdened with several contraindications and poor tolerability. A better understanding of HCV-associated glucose metabolism derangements and their reversibility is expected with the use of DAAs.